查看文章

We read with interest the recent meta-analysis assessing the clinical efficacy and safety of nirmatrelvir plus ritonavir (NMV-r) in the treatment of patients with COVID-19. 1 Based on the analysis of 13 studies involving 186,306 patients, the authors concluded that NMV-r was effective in reducing the mortality (odds ratio [OR], 0.12; 95% CI, 0.04-0.36) and the risk of hospitalization (OR, 0.32; 95% CI, 0.13-0.75) for patients with COVID-19. 1 These findings indicated that NMV-r could be a useful antiviral treatment for COVID-19. However, it was also noted that a significant proportion of individuals who have recovered from acute COVID-19 may experience long-term complications, a phenomenon referred to as long COVID. 2, 3 Moreover, long COVID has been shown to have a negative impact on both physical and mental well-being. 2, 3 Therefore, how to prevent the development of long COVID has become a serious …